FDA meeting focuses Nicox on new indication for NCX 4251

8 February 2022

French ophthalmology company Nicox (Euronext: COX) has said it will focus future development of its candidate NCX 4251 on dry eye disease.

Nicox said the strategic update is based on “encouraging post hoc results from the Mississippi Phase IIb clinical trial,” as well as a “positive meeting” with the US regulator.

The results, reported in November 2021, suggest that once-daily dosed NCX 4251, fluticasone propionate, is effective in reducing dry eye symptoms in patients who score more highly for a key sign of the condition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK